Processa Pharmaceuticals, Inc.
PCSA
$2.55
-$0.01-0.39%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.08% | 21.53% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.11% | -11.69% | |||
| Operating Income | -6.11% | 11.69% | |||
| Income Before Tax | 2.26% | 12.64% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 2.26% | 12.64% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 2.26% | 12.64% | |||
| EBIT | -6.11% | 11.69% | |||
| EBITDA | -6.11% | 11.69% | |||
| EPS Basic | 17.66% | 71.38% | |||
| Normalized Basic EPS | 17.65% | 71.38% | |||
| EPS Diluted | 17.66% | 71.38% | |||
| Normalized Diluted EPS | 17.65% | 71.38% | |||
| Average Basic Shares Outstanding | 18.70% | 205.23% | |||
| Average Diluted Shares Outstanding | 18.70% | 205.23% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||